- The Oracle of Omaha, Warren Buffett, has increased his portfolio's exposure to Bitcoin-friendly companies like Nubank.
- Based on a recent SEC filing, Berkshire Hathaway dumped Visa and Mastercard stocks in favor of Nubank, a Brazilian neobank.
- The firm purchased $1 billion worth of Nubank shares in Q4 2021.
American business magnate Warren Buffett's firm Berkshire Hathaway sold Visa and Mastercard stocks and increased exposure in the most prominent Brazilian fintech bank, Nubank. Buffett has addressed Bitcoin as "rat poison squared," however the latest SEC filing reveals his interest in BTC-friendly companies.
Berkshire Hathaway added $250 million in Nubank shares in Q4 2021
Warren Buffett's firm Berkshire Hathaway sold payment giant Visa and Mastercard stocks to acquire 40 million Nubank shares worth $1 billion in Q4 2021. Nubank is Brazil's largest fintech bank, a Bitcoin-friendly firm, popular among investors.
In a Securities & Exchange Commission (SEC) filing on February 14, Berkshire Hathaway disclosed the purchase of Nubank's Class A stocks. The firm sold $3.1 billion in Visa and Mastercard stocks, reducing exposure to credit companies.
Buffett is best known for his critique of Bitcoin; the business magnate used the term "rat poison squared" to describe the cryptocurrency. Despite the veteran investors' approach to Bitcoin, there is a rise in Berkshire Hathaway's exposure to BTC-friendly firms and institutions.
Nubank is a fintech bank that allows users to invest in cryptocurrency ETFs, and Berkshire Hathaway has no intention of reducing exposure to the firm. Berkshire Hathaway's recent investment decisions show the acknowledgment of the rise in Bitcoin mainstream acceptance and adoption.
Fintech companies have added Bitcoin to their balance sheet or rapidly offered related services to users over the past two years, as the asset gained higher popularity. Berkshire Hathaway's willingness to associate with a Bitcoin-friendly fintech giant fuels a bullish narrative for Bitcoin price.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.